{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:53:19Z","timestamp":1787500399055,"version":"build-2736575974"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    To improve the prognosis and maintain quality of life in patients with peritoneal metastasis (PM), a novel treatment has been introduced\u2013pressurized intraperitoneal aerosol chemotherapy (PIPAC). The majority of teams propose at least 3 PIPAC procedures. However, for many patients PIPAC is stopped after only one or two procedures. The aim of this study was to identify the reasons for stopping PIPAC after only one or two procedures and to establish a profile of poor candidates. This retrospective, multicenter cohort study included all patients who underwent PIPAC in three French expert centers between 2015 and 2021. A total of 268 PIPAC procedures were performed in 89 patients. Of them, 48.3% of patients underwent fewer than three procedures: 28.1% had one, 20.2% two and 51.7% three or more PIPAC procedures. The main reason for stopping PIPAC, regardless of the number of procedures, was disease progression, in 55.8% of cases. Other reasons for stopping PIPAC were non-access to the abdominal cavity (7.9%), conversion to cytoreductive surgery (13.5%), post-PIPAC adverse events (7.9%), patients\u2019 wishes (10.1%) and death (2.2%). In univariate analysis, patients who received fewer than three PIPACs less frequently had chemotherapy beforehand (91% vs 100%,\n                    <jats:italic>p = 0<\/jats:italic>\n                    .\n                    <jats:italic>05<\/jats:italic>\n                    ), less frequently had bimodal treatment (70% vs 87%,\n                    <jats:italic>p = 0<\/jats:italic>\n                    .\n                    <jats:italic>04<\/jats:italic>\n                    ), had more ascites (median 80 ml vs 50 ml,\n                    <jats:italic>p = 0<\/jats:italic>\n                    .\n                    <jats:italic>05<\/jats:italic>\n                    ) and more frequently had carcinomatosic ascites (48.8% vs 23.9%,\n                    <jats:italic>p &lt; 0<\/jats:italic>\n                    .\n                    <jats:italic>01<\/jats:italic>\n                    ). Performing PIPAC alone in chemotherapy-na\u00efve patients with ascites should be avoided.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0287785","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T13:59:23Z","timestamp":1701352763000},"page":"e0287785","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reasons for stopping Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC): A retrospective study to improve future patient selection"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0270-5090","authenticated-orcid":true,"given":"Anne-C\u00e9cile","family":"Ezanno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brice","family":"Malgras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Louis","family":"Conan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Aime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Fawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Picchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol\u00e8ne","family":"Doat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pocard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"issue":"7","key":"pone.0287785.ref001","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","article-title":"Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications","volume":"20","author":"M Alyami","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"pone.0287785.ref002","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/bjs.10521","article-title":"Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis","volume":"104","author":"F Grass","year":"2017","journal-title":"Br J Surg"},{"issue":"4","key":"pone.0287785.ref003","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1515\/pp-2021-0125","article-title":"Consensus statement on safety measures for pressurized intraperitoneal aerosol chemotherapy","volume":"6","author":"A Girardot-Miglierina","year":"2021","journal-title":"Pleura Peritoneum"},{"key":"pone.0287785.ref004","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920940887","article-title":"Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma","volume":"12","author":"A Di Giorgio","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"pone.0287785.ref005","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/s12885-018-4363-0","article-title":"Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma","volume":"18","author":"U Giger-Pabst","year":"2018","journal-title":"BMC Cancer"},{"issue":"10","key":"pone.0287785.ref006","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.3390\/cancers14102557","article-title":"Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases","volume":"14","author":"A Balmer","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"pone.0287785.ref007","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.ejso.2017.09.010","article-title":"Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis","volume":"43","author":"M Alyami","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"pone.0287785.ref008","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejso.2020.08.020","article-title":"ISSPP PIPAC study group. Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): still standardized or on the verge of diversification?","volume":"47","author":"O Sgarbura","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"pone.0287785.ref009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/pp-2022-0102","article-title":"Consensus statement for treatment protocols in pressurized intraperitoneal aerosol chemotherapy (PIPAC)","volume":"7","author":"O Sgarbura","year":"2022","journal-title":"Pleura Peritoneum"},{"issue":"1","key":"pone.0287785.ref010","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.21037\/jgo-20-497","article-title":"The emergence of pressurized intraperitoneal aerosol chemotherapy as a palliative treatment option for patients with diffuse peritoneal metastases: a narrative review","volume":"12","author":"RJ Lurvink","year":"2021","journal-title":"J Gastrointest Oncol"},{"issue":"2","key":"pone.0287785.ref011","doi-asserted-by":"crossref","first-page":"20180116","DOI":"10.1515\/pp-2018-0116","article-title":"PIPAC EstoK 01: Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin (PIPAC C\/D) in gastric peritoneal metastasis: a randomized and multicenter phase II study","volume":"3","author":"C Eveno","year":"2018","journal-title":"Pleura Peritoneum"},{"issue":"3","key":"pone.0287785.ref012","doi-asserted-by":"crossref","first-page":"20180120","DOI":"10.1515\/pp-2018-0120","article-title":"Phase I\/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): Rationale and design","volume":"3","author":"F Dumont","year":"2018","journal-title":"Pleura Peritoneum"},{"issue":"4","key":"pone.0287785.ref013","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ejso.2021.10.028","article-title":"Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: Technical aspects and treatment protocols","volume":"48","author":"M H\u00fcbner","year":"2022","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"pone.0287785.ref014","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jviscsurg.2019.01.006","article-title":"PIPAC: 8 key points for a good practice with video","volume":"156","author":"G Mariano","year":"2019","journal-title":"J Visc Surg"},{"issue":"1","key":"pone.0287785.ref015","doi-asserted-by":"crossref","first-page":"20190004","DOI":"10.1515\/pp-2019-0004","article-title":"Staging laparoscopy and Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for peritoneal metastasis: safe access to the abdomen","volume":"4","author":"T Glatz","year":"2019","journal-title":"Pleura Peritoneum"},{"issue":"4","key":"pone.0287785.ref016","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.ajog.2004.05.004","article-title":"Ten-year experience with laparoscopy on a gynecologic oncology service: analysis of risk factors for complications and conversion to laparotomy","volume":"191","author":"DS Chi","year":"2004","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"pone.0287785.ref017","first-page":"373","article-title":"First Clinical Data of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as Salvage Therapy for Peritoneal Metastatic Biliary Tract Cancer","volume":"38","author":"TA Falkenstein","year":"2018","journal-title":"Anticancer Res"},{"issue":"9","key":"pone.0287785.ref018","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1245\/s10434-020-09508-0","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy for Colorectal Peritoneal Metastases","volume":"28","author":"N Tabchouri","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"pone.0287785.ref019","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10585-018-9895-9","article-title":"Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature survey","volume":"35","author":"M Graversen","year":"2018","journal-title":"Clin Exp Metastasis"},{"issue":"12","key":"pone.0287785.ref020","first-page":"6723","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy with Cisplatin and Doxorubicin in Women with Peritoneal Carcinomatosis: A Cohort Study","volume":"35","author":"CB Tempfer","year":"2015","journal-title":"Anticancer Res"},{"issue":"2","key":"pone.0287785.ref021","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11605-015-2995-9","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis","volume":"20","author":"G Nadiradze","year":"2016","journal-title":"J Gastrointest Surg"},{"issue":"4","key":"pone.0287785.ref022","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/codi.13130","article-title":"Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis","volume":"18","author":"C Demtr\u00f6der","year":"2016","journal-title":"Colorectal Dis"},{"key":"pone.0287785.ref023","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12957-016-0892-7","article-title":"Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis","volume":"14","author":"M Robella","year":"2016","journal-title":"World J Surg Oncol"},{"issue":"1","key":"pone.0287785.ref024","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/0300891619868013","article-title":"Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in patients with peritoneal metastasized colorectal, appendiceal and small bowel cancer","volume":"106","author":"I Gockel","year":"2020","journal-title":"Tumori"},{"issue":"1","key":"pone.0287785.ref025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejso.2020.05.021","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer","volume":"47","author":"M Alyami","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"pone.0287785.ref026","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejso.2019.06.028","article-title":"Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"47","author":"M Alyami","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"pone.0287785.ref027","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/DCR.0000000000001565","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy, a Palliative Treatment Approach for Patients With Peritoneal Carcinomatosis: Description of Method and Systematic Review of Literature","volume":"63","author":"CS Winkler","year":"2020","journal-title":"Dis Colon Rectum"},{"key":"pone.0287785.ref028","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.suronc.2020.05.006","article-title":"Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis","volume":"34","author":"A Di Giorgio","year":"2020","journal-title":"Surg Oncol"},{"issue":"8","key":"pone.0287785.ref029","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1245\/s10434-022-11577-2","article-title":"Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study","volume":"29","author":"A Taibi","year":"2022","journal-title":"Ann Surg Oncol"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0335021","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0287785","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T13:59:40Z","timestamp":1701352780000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0287785"}},"subtitle":[],"editor":[{"given":"Fabrizio","family":"D\u2019Acapito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0287785","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]}}}